
Shareholdings moves in Q4: Pledging peril hits smallcaps, escalating investor worries
Imagine a tightrope walker in a storm—that's akin to promoters of several BSE-listed companies in the March 2025 quarter. Buffeted by volatile markets, they sharply rejigged their pledged shareholdings, a tell-tale sign of rising financial pressure. A deep dive by Mint into 3,716 BSE entities reveals this dramatic churn, particularly highlighting the growing strain on smaller players as they navigate the unpredictable economic winds.
While the number of companies where promoter pledging exceeded 90% dipped slightly to 34 in Q4FY25 from 35 in the December quarter and 40 a year ago, the trend still highlights persistent stress. "Promoter pledging signals corporate finance stress and governance risk. A high pledge indicates risks the company might face. Studies show companies with high promoter pledges see higher market volatility. Promoters' shares, held as collateral, can be sold to recoup losses. In a price crash, lenders may panic sell, triggering a market spree," said Vivek Sharma, head of investment at Estee Advisors.
'Moreover, pledging is costly, with lenders imposing high interest rates and strict loan-to-value ratios. This pressures future earnings, requiring growth above capital costs to create value. While not always leading to poor performance, high pledging shows a strong correlation with it," he added.
Flashpoints of concern
The steepest rise in promoter pledging is concentrated in small-cap companies, the Mint analysis shows, whose falling stock prices point to mounting investor anxiety about their financial foundations.
Topping the list is IL&FS Investment Managers, a financial services firm, where promoter pledging spiked from zero to 100% in just one quarter. The market reacted sharply, with the stock falling 18.93% during the same period. Real estate player Marathon Nextgen Realty followed closely, as its promoters increased pledged shares from nil to 91.46%, resulting in a 12.02% drop in its stock price.
Auto component manufacturer NRB Bearings also saw a significant rise in promoter pledging, reaching 91.35%, while its share price declined 27.97%. Even companies that had relatively lower promoter pledging levels to begin with weren't spared after steep increases. In the case of textile exporter Gokaldas Exports, pledging rose dramatically from 22.37% to 96.28%, triggering the steepest fall among the group, with the stock tumbling 28.84%. Meanwhile, chemicals and flooring products manufacturer Royal Cushion Vinyl Products reported an increase in promoter pledging from 3.86% to 76.5%, alongside a 3.28% dip in its share price.
Harshal Dasani, business head at INVasset PMS, noted, 'The March 2025 quarter has reinforced a shift in investor psychology—any form of promoter pledging, whether rising or falling, is now met with suspicion. Markets are punishing even firms that reduced pledged shares, signalling that investors are reacting not just to the direction of pledging, but to its very existence."
This heightened scrutiny stems from tighter liquidity, macroeconomic volatility, and governance scandals in the mid- and small-cap space. 'Even strategic pledging for business expansion is now under the scanner," Dasani added.
'There is also a risk that the promoter might lose control of management in distressed market conditions. Since promoters are often key personnel in the operations of the organization, a high pledge, especially above 50%, raises concerns among investors," said Sharma.
Also read Shareholdings moves in Q4: Indian Inc's founders hike stakes in select small-cap firms
Good news falls flat
Supporting Dasani's claims, even drastic cuts in promoter pledging failed to prevent significant stock price declines. For instance, Inditrade Capital's complete reduction from 96.4% to zero was followed by a 51% drop in the March quarter. Future Market Networks experienced a similar fate, with a 40.6% price erosion despite zero pledging, all while the market experienced a shaky uptrend in that quarter.
Pakka, which operates in paper and packaging, reduced promoter pledging from 85% to 9%, but saw a 46.4% slump in its stock. Aster DM Healthcare and Bedmutha Industries also faced stock declines despite lowering their pledges.
'Empirical studies have found that while high promoter pledging does not always lead to poor performance, there is a high correlation between the two," Sharma highlighted.
This is the concluding part of a series of data stories on the latest shareholding pattern. Read previous parts of our shareholding series here.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Mint
4 hours ago
- Mint
Anant Ambani to get THIS amount as salary as Executive Director of Reliance — Check details
Mukesh Ambani-run oil marketing major Reliance Industries appointed Anant Ambani as one of the company's Full-Time directors. As a board member, Anant Ambani will be paid ₹ 10 crore to ₹ 20 crore, according to an exchange filing on Sunday, 29 June 2025. The filing data shows that Ambani's annual salary will comprise the main salary component, along with perquisites and allowances. The company also highlighted that the annual increments will be determined by the HRNR Committee at Reliance. 'Salary, Perquisites and Allowances shall be in the range of ₹ 10 crore to ₹ 20 crore per annum. Annual increments shall be as determined by the HRNR Committee,' said Reliance in its BSE filing. The perquisites and allowances will include accommodation cost or house rent allowance, gas, electricity, water, among other provisions as per the Income Tax Act of 1961. Reliance's contribution to Anant Ambani's provident fund, superannuation or annuity fund, gratuity payable and encashment of leave will be carried out as per the rules of the firm. However, these extra benefits will be provided in addition to Anant Ambani's salary of ₹ 10-20 crore. On top of the take-home salary, Anant Ambani will also receive an extra payment based on the net profits of the company. The company will also grant reimbursements on expenses incurred by Anant Ambani, his wife and attendant's travelling, boarding and lodging, according to the company's disclosure. According to the official filing data, the board of directors held their meeting on 15 April 2025, and approved the appointment of Anant Ambani a the Whole-time Director, designated as an Executive Director for the next five years effective 1 May 2025. His salary component also comes along with security and medical reimbursement as per Reliance's policy for senior managerial executives. Anant Ambani has been appointed as the Whole-Time director at Reliance along with his Executive Director position for the next five years, effective 1 May 2025. 'The Board of Directors of the Company, at its meeting held on 25 April 2025, subject to the approval of members, appointed Shri Anant M. Ambani (DIN: 07945702) as a Whole-time Director, designated as an Executive Director, for a period of 5 (five) years, with effect from 1 May 2025,' said the company in the exchange filing.

Mint
4 hours ago
- Mint
Torrent Pharma to acquire majority stake in KKR-backed JB Chemicals at ₹25,689 crore valuation — Details here
Gujarat-based pharmaceutical giant Torrent Pharma announced on Sunday, 29 June 2025, that it is in definitive agreements with global investment giant KKR to acquire a majority stake in JB Chemicals, according to an exchange filing. The potential acquisition details show that the company plans to acquire J. B. Chemicals and Pharmaceuticals (JB Pharma) at an equity valuation of ₹ 25,689 crore on a fully diluted basis, which will be followed by a merger of the two companies. JB Pharma's promoter company, Tau Investment Holdings, is a KKR-owned investment vehicle which the global giant uses to own a stake in the pharma major. Tau Investment is a legally distinct legal entity of KKR & Co. Inc. Tau Investment currently holds a 47.84% stake in J. B. Chemicals and Pharmaceuticals, according to BSE data as on Sunday, 29 June 2025. The deal is set to be carried out in several phases. In the first phase, Torrent Pharma will acquire a 46.39% stake through a share purchase agreement (SPA), which will total ₹ 11,917 crore at the rate of ₹ 1,600 per share. After the first phase, the company will introduce a mandatory open offer to acquire up to 26% of JB Pharma shares from public stakeholders at an open offer price of ₹ 1,639.18 per share. The acquiring company also plans to acquire another 2.80% stake in the company from certain employees holding a stake of JB Pharma at the same price per share as KKR selling its stake. The company also announced its plans for a merger between Torrent and JB Pharma through a scheme of arrangement where every shareholder holding 100 shares in JB Pharma will receive 51 shares of Torrent Pharmaceuticals. 'We are pleased to have on board the JB Pharma heritage and build on the platform for the future. Torrent's deep India presence and JB Pharma's fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability,' said Samir Mehta, the Executive Chairman of Torrent Pharma in the official statement. JB Chemicals & Pharmaceuticals shares closed 2.72% higher at ₹ 1,799.35 after Friday's stock market session, compared to ₹ 1,751.75 in the previous market close. Shares of the pharma company have given more than 398% returns on investment in the last five years. However, the stock has lost 0.03% in the last one-year period. On a year-to-date (YTD) basis, the shares are down 4.58% in 2025, but are currently trading 6.02% higher in the last one-month period. Torrent Pharmaceuticals shares also closed with 3.68% gains on Friday's market at ₹ 3,344.40, compared to ₹ 3,225.70 in the previous stock market session last week. Pharma major Torrent Pharmaceuticals shares have gained 181% in the last five years and are trading 21.35% higher in the last one-year period. The shares are trading 6.94% higher in the last five trading sessions. Read all stories by Anubhav Mukherjee

Mint
5 hours ago
- Mint
Torrent Pharma to acquire majority stake in KKR-backed JB Chemicals at ₹25,689 crore valuation — Details here
Gujarat-based pharmaceutical giant Torrent Pharma announced on Sunday, 29 June 2025, that it is in definitive agreements with global investment giant KKR to acquire a majority stake in JB Chemicals, according to an exchange filing. The potential acquisition details show that the company plans to acquire J. B. Chemicals and Pharmaceuticals (JB Pharma) at an equity valuation of ₹ 25,689 crore on a fully diluted basis, which will be followed by a merger of the two companies. JB Pharma's promoter company, Tau Investment Holdings, is a KKR-owned investment vehicle which the global giant uses to own a stake in the pharma major. Tau Investment is a legally distinct legal entity of KKR & Co. Inc. Tau Investment currently holds a 47.84% stake in J. B. Chemicals and Pharmaceuticals, according to BSE data as on Sunday, 29 June 2025. The deal is set to be carried out in several phases. In the first phase, Torrent Pharma will acquire a 46.39% stake through a share purchase agreement (SPA), which will total ₹ 11,917 crore at the rate of ₹ 1,600 per share. After the first phase, the company will introduce a mandatory open offer to acquire up to 26% of JB Pharma shares from public stakeholders at an open offer price of ₹ 1,639.18 per share. The acquiring company also plans to acquire another 2.80% stake in the company from certain employees holding a stake of JB Pharma at the same price per share as KKR selling its stake. The company also announced its plans for a merger between Torrent and JB Pharma through a scheme of arrangement where every shareholder holding 100 shares in JB Pharma will receive 51 shares of Torrent Pharmaceuticals. 'We are pleased to have on board the JB Pharma heritage and build on the platform for the future. Torrent's deep India presence and JB Pharma's fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability,' said Samir Mehta, the Executive Chairman of Torrent Pharma in the official statement. JB Chemicals & Pharmaceuticals shares closed 2.72% higher at ₹ 1,799.35 after Friday's stock market session, compared to ₹ 1,751.75 in the previous market close. Shares of the pharma company have given more than 398% returns on investment in the last five years. However, the stock has lost 0.03% in the last one-year period. On a year-to-date (YTD) basis, the shares are down 4.58% in 2025, but are currently trading 6.02% higher in the last one-month period. Torrent Pharmaceuticals shares also closed with 3.68% gains on Friday's market at ₹ 3,344.40, compared to ₹ 3,225.70 in the previous stock market session last week. Pharma major Torrent Pharmaceuticals shares have gained 181% in the last five years and are trading 21.35% higher in the last one-year period. The shares are trading 6.94% higher in the last five trading sessions. Read all stories by Anubhav Mukherjee Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.